For years, the KRAS oncogene was considered a key cancer driver but impossible to target with drugs. Through resilient investigation, scientists recently developed effective therapies against it, proving that even long-held beliefs about 'undruggable' targets can be overturned with persistence.

The traditional practice of classifying recurrent ovarian cancer as 'platinum-sensitive' or 'platinum-resistant' based on a six-month treatment-free interval is rapidly becoming obsolete. The introduction of maintenance therapies like PARP inhibitors is changing tumor biology and response patterns, suggesting this simple time-based distinction no longer adequately reflects the clinical reality.

Despite targeting the KRAS pathway, mutated in ~95% of pancreatic cancers, the pivotal study enrolled all patients regardless of mutation status. This "all-comers" approach simplifies recruitment and, if approved, could lead to a broad label without requiring prerequisite genetic testing, potentially because the drug impacts the entire RAS pathway.

The new drug avutometinib uses a "RAF-MEK clamp" mechanism, blocking two nodes in the RAS pathway simultaneously (RAF and MEK). This dual-inhibition strategy is more effective than single-node targeting because it preempts the cancer cell's adaptive resistance mechanisms, where the pathway reactivates itself in response to upstream blocking.

Contrary to expectations, less common gynecologic cancers like low-grade serous, mucinous, and clear cell ovarian cancers are highly enriched with RAS/MAP kinase pathway mutations (40-70%). This contrasts with high-grade serous ovarian cancer, the most common subtype, which has fewer such mutations, making rare subtypes key targets for new therapies.

The future of GYN oncology immunotherapy is diverging. For responsive cancers like endometrial, the focus is on refining biomarkers and overcoming resistance. For historically resistant cancers like ovarian, the strategy shifts to using combinatorial approaches (e.g., CAR-NKs, vaccines) to fundamentally alter the tumor microenvironment itself, making it more receptive to an immune response.

In the rare scenario of colorectal cancer with both HER2 amplification and a KRAS G12C mutation, US-based experts might prioritize KRAS-directed therapy. This preference is driven by durable data for KRAS inhibitors, even though choosing between targets is difficult without direct comparative studies.

Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.

The RAS/MAP kinase pathway is an "underrecognized" and "underutilized" therapeutic target in endometrial cancers. Despite up to a quarter of these cancers having mutations in pathway genes, clinical focus has often been elsewhere. This highlights a significant, overlooked opportunity for applying RAS-targeted therapies to a broader patient population.